Cancer Chemotherapy and Pharmacology

, Volume 84, Issue 6, pp 1229–1239 | Cite as

ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer

  • Takehiro Uemura
  • Tetsuya OguriEmail author
  • Ken Maeno
  • Kazuki Sone
  • Akira Takeuchi
  • Satoshi Fukuda
  • Eiji Kunii
  • Osamu Takakuwa
  • Yoshihiro Kanemitsu
  • Hirotsugu Ohkubo
  • Masaya Takemura
  • Yutaka Ito
  • Akio Niimi
Original Article



ABCC11/MRP8 (ABCC11) is an ATP-binding cassette transporter that is involved in regulating cellular sensitivity and resistance for many anti-cancer drugs. Since 5-fluorouracil (5-FU) is one of the substrates for ABCC11, we examined whether ABCC11 is a predictive marker for an oral 5-FU derivative drug S-1 treatment in non-small cell lung cancer (NSCLC).


Real-time PCR and MTS assay were carried on 21 human NSCLC cell lines. The drug resistance capabilities of ABCC11 are evaluated by analyzing the resistance profiles of a clone of HeLa cell in which the pump was ectopically expressed. Blood samples of 106 NSCLC patients were collected.


There was a significant correlation between dihydropyrimidine dehydrogenase (DPD) gene expression and the IC50 for 5-FU. We then classified NSCLC cell lines into two groups based on the phenotype of the SNP538 (G > A) in ABCC11: a combined G/G and G/A group, and an A/A group. The distribution of the IC50 for 5-FU in combination with a potent inhibitor of DPD 5-chloro-2, 4-dihydropyrimidine (CDHP), which is contained in S-1, showed a significant reduction in the A/A group compared with the combined G/G and G/A group. Next, the clinical usefulness of the ABCC11 SNP in treatment containing S-1 was examined in 106 NSCLC patients, and the disease control rate was found to be significantly better in the A/A group than in the combined G/G and G/A group.


These results indicate that the SNP538(G > A) in the ABCC11 gene is a potential determinant for S-1 treatment.


ABCC11/MRP8 5-fluorouracil (5-FU) S-1 Single-nucleotide polymorphism (SNP) Thymidylate synthase (TS) 



This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (MEXT/JSPSKAKENHI23591156).

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

280_2019_3959_MOESM1_ESM.pptx (43 kb)
Supplementary material 1 (PPTX 42 kb)
280_2019_3959_MOESM2_ESM.pptx (63 kb)
Supplementary material 2 (PPTX 62 kb)
280_2019_3959_MOESM3_ESM.docx (17 kb)
Supplementary material 3 (DOCX 17 kb)
280_2019_3959_MOESM4_ESM.docx (15 kb)
Supplementary material 4 (DOCX 15 kb)


  1. 1.
    Malet-Martino M, Martino R (2002) Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7:288–323CrossRefGoogle Scholar
  2. 2.
    Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H, Fukushima M (1999) Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5:883–889PubMedGoogle Scholar
  3. 3.
    Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412PubMedGoogle Scholar
  4. 4.
    Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S, Ueda R (2005) The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49:345–351. CrossRefPubMedGoogle Scholar
  5. 5.
    Fukushima M, Morita M, Ikeda K, Nagayama S (2003) Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 12:839–844PubMedGoogle Scholar
  6. 6.
    Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713–1721. CrossRefPubMedGoogle Scholar
  7. 7.
    Okamoto I, Fukuoka M (2009) S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 10:290–294. CrossRefPubMedGoogle Scholar
  8. 8.
    Saif MW, Syrigos KN, Katirtzoglou NA (2009) S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 18:335–348. CrossRefPubMedGoogle Scholar
  9. 9.
    Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048–4054PubMedGoogle Scholar
  10. 10.
    Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD (2003) MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem 278:29509–29514. CrossRefPubMedGoogle Scholar
  11. 11.
    Uemura T, Oguri T, Ozasa H, Takakuwa O, Miyazaki M, Maeno K, Sato S, Ueda R (2010) ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci 101:2404–2410. CrossRefPubMedGoogle Scholar
  12. 12.
    Oguri T, Bessho Y, Achiwa H, Ozasa H, Maeno K, Maeda H, Sato S, Ueda R (2007) MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 6:122–127. CrossRefPubMedGoogle Scholar
  13. 13.
    Pesce MA, Bodourian SH (1986) Evaluation of a fluorescence polarization immunoassay procedure for quantitation of methotrexate. Ther Drug Monit 8:115–121CrossRefGoogle Scholar
  14. 14.
    Yoshiura K, Kinoshita A, Ishida T, Ninokata A, Ishikawa T, Kaname T, Bannai M, Tokunaga K, Sonoda S, Komaki R, Ihara M, Saenko VA et al (2006) A SNP in the ABCC11 gene is the determinant of human earwax type. Nat Genet 38:324–330. CrossRefPubMedGoogle Scholar
  15. 15.
    Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD (2005) Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol 67:545–557. CrossRefPubMedGoogle Scholar
  16. 16.
    Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Kashiwaba M, Oyama K, Takahashi M, Maesawa C, Saito K, Takechi T, Fukushima M (2002) Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 93:1342–1350CrossRefGoogle Scholar
  17. 17.
    Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ (2004) Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2′-deoxyuridine. World J Gastroenterol 10:172–176PubMedPubMedCentralGoogle Scholar
  18. 18.
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327PubMedGoogle Scholar
  19. 19.
    Takechi T, Fujioka A, Matsushima E, Fukushima M (2002) Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38:1271–1277CrossRefGoogle Scholar
  20. 20.
    Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28:5240–5246. CrossRefPubMedGoogle Scholar
  21. 21.
    Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M et al (2013) Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol 24:1326–1331. CrossRefPubMedGoogle Scholar
  22. 22.
    Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T et al (2017) Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 28:2698–2706. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M et al (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373:1627–1639. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N et al (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373:123–135. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837–1846. CrossRefPubMedGoogle Scholar
  26. 26.
    Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550. CrossRefPubMedGoogle Scholar
  27. 27.
    Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H (2004) S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10:7860–7864. CrossRefPubMedGoogle Scholar
  28. 28.
    Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K, Tsutsumi Y (2005) Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 14:1223–1230PubMedGoogle Scholar
  29. 29.
    Shaul YD, Freinkman E, Comb WC, Cantor JR, Tam WL, Thiru P, Kim D, Kanarek N, Pacold ME, Chen WW, Bierie B, Possemato R et al (2014) Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell 158:1094–1109. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19:1438–1449. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R (2010) Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 101:161–166. CrossRefPubMedGoogle Scholar
  32. 32.
    Toyoda Y, Sakurai A, Mitani Y, Nakashima M, Yoshiura K, Nakagawa H, Sakai Y, Ota I, Lezhava A, Hayashizaki Y, Niikawa N, Ishikawa T (2009) Earwax, osmidrosis, and breast cancer: why does one SNP (538G > A) in the human ABC transporter ABCC11 gene determine earwax type? FASEB J 23:2001–2013. CrossRefPubMedGoogle Scholar
  33. 33.
    Toyoda Y, Gomi T, Nakagawa H, Nagakura M, Ishikawa T (2016) Diagnosis of Human Axillary Osmidrosis by Genotyping of the Human ABCC11 Gene: clinical Practice and Basic Scientific Evidence. Biomed Res Int 2016:7670483. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Toyoda Y, Takada T, Gomi T, Nakagawa H, Ishikawa T, Suzuki H (2017) Clinical and Molecular Evidence of ABCC11 Protein Expression in Axillary Apocrine Glands of Patients with Axillary Osmidrosis. Int J Mol Sci. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Tsuchiya T, Arai J, Matsumoto K, Miyazaki T, Honda S, Tagawa T, Nakamura A, Taniguchi H, Sano I, Akamine S, Muraoka M, Hisano H et al (2016) Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer. Chemotherapy 61:77–86. CrossRefPubMedGoogle Scholar
  36. 36.
    Hotta K, Fujiwara Y, Kiura K, Takigawa N, Tabata M, Ueoka H, Tanimoto M (2007) Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2:402–407. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Takehiro Uemura
    • 1
    • 2
  • Tetsuya Oguri
    • 3
    Email author
  • Ken Maeno
    • 1
  • Kazuki Sone
    • 1
  • Akira Takeuchi
    • 1
  • Satoshi Fukuda
    • 1
  • Eiji Kunii
    • 4
  • Osamu Takakuwa
    • 1
  • Yoshihiro Kanemitsu
    • 1
  • Hirotsugu Ohkubo
    • 1
  • Masaya Takemura
    • 1
  • Yutaka Ito
    • 1
  • Akio Niimi
    • 1
  1. 1.Department of Respiratory Medicine, Allergy and Clinical ImmunologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of Thoracic OncologyAichi Cancer Center HospitalNagoyaJapan
  3. 3.Education and Research Center for Community MedicineNagoya City University Graduate School of Medical SciencesNagoyaJapan
  4. 4.Department of Respiratory MedicineNagoya City West Medical CenterNagoyaJapan

Personalised recommendations